KBC Group’s Spyre Therapeutics SYRE Stock Holding History

KBC Group’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$159K	Buy	1,796 +424	+31%	+$30.9K	﹤0.01%	1136
2026 Q1	$69K	Buy	+1,372	New	+$51.7K	﹤0.01%	1522

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

KBC Group's SYRE Position: Q2 2026 in Review

KBC Group increased its Spyre Therapeutics (SYRE) stake by 31% in Q2 2026, buying an estimated $30.9K and bringing the position to 1,796 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #1136.

KBC Group first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

KBC Group held 1,796 shares of Spyre Therapeutics worth $159K as of Q2 2026.
KBC Group bought 424 Spyre Therapeutics shares in Q2 2026, an estimated $30.9K.
Spyre Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1136 holding.
KBC Group first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.